Table 1 Characteristics of study subjects before and after treatment
Control (n = 10) | Acarbose (n = 10) | Nateglinide (n = 10) | ||||
|---|---|---|---|---|---|---|
Baseline | 12 weeks | Baseline | 12 weeks | Baseline | 12 weeks | |
Age (years) | 68.0 ± 7.7 | 67.6 ± 6.2 | 67.8+/-8.6 | |||
Male gender (%) | 5 (50) | 7 (70) | 7 (70) | |||
BMI (kg/m2) | 26.8 ± 3.2 | 26.1 ± 3.4 | 25.8 ± 2.5 | 25.3 ± 7.4 | 25.8 ± 3.3 | 25.5 ± 2.9 |
Total cholesterol (mg/dl) | 213.2 ± 15.9 | 210.2 ± 23.2 | 201.8 ± 25.4 | 205.7 ± 38.1 | 206.0 ± 25.4 | 211.1 ± 29.6 |
Triglyceride (mg/dl) | 132.4 ± 13.1 | 127.7 ± 17.1 | 116.1 ± 20.8 | 125.5 ± 34.7 | 121.7 ± 19.3 | 121.6 ± 22.3 |
HDL cholesterol (mg/dl) | 53.8 ± 11.0 | 53.7 ± 9.5 | 56.2 ± 11.0 | 52.7 ± 14.4 | 54.4 ± 12.5 | 57.4 ± 13.2 |
LDL cholesterol (mg/dl) | 135.0 ± 48.8 | 143.9 ± 52.7 | 141.6 ± 69.3 | 137.4 ± 77.3 | 149.4 ± 76.0 | 121.6 ± 22.3 |
HbA1c (%) | 5.8 ± 0.6 | 5.6 ± 0.5 | 6.0 ± 0.3 | 5.9 ± 0.4 | 6.1 ± 0.6 | 5.8 ± 0.4 |
Fasting glucose (mg/dl) | 110.7 ± 15.0 | 109.3 ± 12.0 | 109.6 ± 17.5 | 108.8 ± 15.7 | 119.6 ± 17.5 | 110.4 ± 11.1 |
Fasting insulin (μU/ml) | 7.5 ± 2.9 | 7.2 ± 2.8 | 9.6 ± 5.6 | 10.6 ± 6.8 | 6.6 ± 4.1 | 6.5 ± 2.7 |
HOMA-IR | 2.0 ± 0.7 | 1.9 ± 1.8 | 2.6 ± 1.6 | 2.8 ± 1.9 | 2.0 ± 1.6 | 1.8 ± 0.7 |
Systolic BP (mmHg) | 143.5 ± 28.5 | 145.5 ± 38.2 | 141.1 ± 26.1 | 142.6 ± 19.1 | 141.3 ± 28.5 | 143.8 ± 23.5 |
Diastolic BP (mmHg) | 89.1 ± 19.2 | 89.3 ± 11.9 | 88.1 ± 23.1 | 83.1 ± 38.9 | 88.3 ± 11.9 | 89.1 ± 23.8 |
Heart rate (beats/min) | 68.8 ± 9.8 | 68.8 ± 8.9 | 69.2 ± 11.1 | 62.9 ± 11.2 | 68.2 ± 8.9 | 68.9 ± 8.2 |